Analyst Ratings for Bio-Rad Laboratories Inc. Cl A (BIO)

Updated: 2017-07-29

Shares of Bio-Rad Laboratories Inc. Cl A (NYSE:BIO) have received a consensus rating of Buy from Wall Street analysts. About 30 days ago, BIO was issued an average rating of Overweight.

Of the 4 analysts covering the stock, 3 gave it a buy rating, 1 gave an overweight rating, 0 issued a hold rating, 0 gave an underweight rating, and 0 issued a sell rating. Compared to three months ago, there has been an increase of 2 in the number of analysts with a positive outlook on the stock. Meanwhile, the number of analysts pessimistic about the company has increased by 0.

Many analysts weighed in on price targets for BIO. The highest price target was 275, implying potential capital gains of 16.35 percent. The lowest price target was 245, implying a possible loss of 3.66 percent. Some investors take price targets and stock ratings with a grain of salt, knowing that some analysts can have indirect business with the stocks they cover.

Analysts have revised their earnings estimates upwards for this quarter, by about 14.42 percent on average, compared to last month. The average change in earnings estimates over the last 90 days is -16.21 percent. Meanwhile, fiscal year estimates have been revised upwards by 3.5 percent, compared to last month. If we look at the last 90 days instead, we find a net average change of 6.68 percent in FY estimates.

Another thing investors often look at is the level of agreement among analysts' revisions. 1 analysts made positive revisions to their quarterly estimates over the past month, which can be compared to the 0 analysts that decreased their estimates. Over the same time period, 1 analysts revised their FY earnings estimates upwards, while 0 analysts decreased their estimates.

Analysts estimate earnings of BIO to grow at a rate of 215.57 percent. Another measure frequently examined by investors is the PEG ratio. A lower PEG ratio is favorable, because that is often interpreted as the company being fairly priced relative to its growth rate. Many investors consider PEG ratios between 0 and 1 as preferrable, even though it may be more relevant to compare the ratio to that of a firm's competitors. BIO has a PEG ratio of 1.17.

BIO has traded between a high of 239.91 and a low of 143.39 over the past year. Today's price is 64.84 percent above the 52-week low, and 1.48 percent below the high. BIO has a P/E ratio of 251.45. Investors typically compare the P/E ratio to a company's peers in the industry. The BIO value stock report compares BIO to some of its peers using value stock charts. The market cap of BIO is $7.03 billion. BIO's next earnings release will be on 0000-00-00, which is days away.